Targeting mitochondria for neuroprotection in Parkinson's disease

Antioxidants and Redox Signaling

Volumn 16, Issue 9, 2012, Pages 965-973

  Schapira, Anthony Henry Vernon ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA TOCOPHEROL; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CREATINE; DYNAMIN I; LEVODOPA; MITOCHONDRIAL DNA; NORSELEGILINE; PARKIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PLACEBO; RASAGILINE; REACTIVE OXYGEN METABOLITE; SELEGILINE; SIRTUIN 1; UBIDECARENONE;

APOPTOSIS; AUTOPHAGY; BIOGENESIS; CLINICAL STUDY; DRUG MECHANISM; DRUG METABOLISM; FRIEDREICH ATAXIA; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; INTRACELLULAR SIGNALING; MITOCHONDRIAL TARGETING SIGNAL; NERVE CELL NECROSIS; NEUROPATHOLOGY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RESPIRATORY CHAIN, OXIDATIVE PHOSPHORYLATION AND CELLULAR ENERGETICS; REVIEW; SENESCENCE; STRUCTURE ACTIVITY RELATION; UNIFIED PARKINSON DISEASE RATING SCALE;

ANIMALS; APOPTOSIS; AUTOPHAGY; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; HUMANS; MITOCHONDRIA; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE;

PARKINSONIA;

EID: 84857969901     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.4419     Document Type: Review

References (86)

1. Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, Caballero C, Ferrer I, Obeso JA, and Schapira AH. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol 67: 1464-1472, 2010.
2. Bar AO, Amit T, and Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 355: 169-172, 2004. (Pubitemid 38368730)
3. Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschl M, Gekeler F, Muller-Myhsok B, Gasser T, Tatsch K, and Klopstock T. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 67: 1262-1264, 2006. (Pubitemid 44563840)
4. Blander G and Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem 73: 417-435, 2004. (Pubitemid 39050375)
5. Bogaerts V, Nuytemans K, Reumers J, Pals P, Engelborghs S, Pickut B, Corsmit E, Peeters K, Schymkowitz J, De Deyn PP, Cras P, Rousseau F, Theuns J, and Van BC. Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease. Hum Mutat 29: 832-840, 2008. (Pubitemid 351794134)
6. Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. Cell 125: 1241-1252, 2006. (Pubitemid 43929096)
7. Chen JH, Stoltz DA, Karp PH, Ernst SE, Pezzulo AA, Moninger TO, Rector MV, Reznikov LR, Launspach JL, Chaloner K, Zabner J, and Welsh MJ. Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell 143: 911-923, 2010.
8. Chen JJ and Swope DM. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 45: 878-894, 2005. (Pubitemid 41060227)
9. Cho DH, Nakamura T, and Lipton SA. Mitochondrial dynamics in cell death and neurodegeneration. Cell Mol Life Sci 67: 3435-3447, 2010.
10. Cleeter MW, Cooper JM, and Schapira AH. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 58: 786-789, 1992.
11. Cooper JM, Korlipara LV, Hart PE, Bradley JL, and Schapira AH. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol 15: 1371-1379, 2008.
12. Dagda RK and Chu CT. Mitochondrial quality control: insights on how Parkinson's disease related genes PINK1, parkin, and Omi/HtrA2 interact to maintain mitochondrial homeostasis. J Bioenerg Biomembr 41: 473-479, 2009.
13. Deng H, Dodson MW, Huang H, and Guo M. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc Natl Acad Sci USA 105: 14503-14508, 2008.
14. Gegg ME, Cooper JM, Chau KY, Rojo M, Schapira AH, and Taanman JW. Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Hum Mol Genet 19: 4861-4870, 2010.
15. Gegg ME and Schapira AH. PINK1-parkin-dependent mitophagy involves ubiquitination of mitofusins 1 and 2: Implications for Parkinson disease pathogenesis. Autophagy 7: 243-245, 2011.
16. Geisler S, Holmstrom KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, and Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol 12: 119-131, 2010.
17. Gerlach M, Foley P, and Riederer P. The relevance of preclinical studies for the treatment of Parkinson's disease. J Neurol 250 Suppl 1: I31-I34, 2003. (Pubitemid 36255754)
18. Ghezzi D, Sevrioukova I, Invernizzi F, Lamperti C, Mora M, D'Adamo P, Novara F, Zuffardi O, Uziel G, and Zeviani M. Severe X-linked mitochondrial encephalomyopathy associated with a mutation in apoptosis-inducing factor. Am J Hum Genet 86: 639-649, 2010.
19. Hart PE, Lodi R, Rajagopalan B, Bradley JL, Crilley JG, Turner C, Blamire AM, Manners D, Styles P, Schapira AH, and Cooper JM. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 62: 621-626, 2005. (Pubitemid 40489896)
20. Heikkila RE, Manzino L, Cabbat FS, and Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467-469, 1984. (Pubitemid 14035453)
21. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, and Sinclair DA. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196, 2003. (Pubitemid 37150899)
22. Jin F, Wu Q, Lu YF, Gong QH, and Shi JS. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur J Pharmacol 600: 78-82, 2008.
23. Karbowski M. Mitochondria on guard: role of mitochondrial fusion and fission in the regulation of apoptosis. Adv Exp Med Biol 687: 131-142, 2010.
24. Khan MM, Ahmad A, Ishrat T, Khan MB, Hoda MN, Khuwaja G, Raza SS, Khan A, Javed H, Vaibhav K, and Islam F. Resveratrol attenuates 6-hydroxydopamine- induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res 1328: 139-151, 2010.
25. Kim Y, Park J, Kim S, Song S, Kwon SK, Lee SH, Kitada T, Kim JM, and Chung J. PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. Biochem Biophys Res Commun 377: 975-980, 2008.
26. Kupsch A, Sautter J, Gotz ME, Breithaupt W, Schwarz J, Youdim MB, Riederer P, Gerlach M, and Oertel WH. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm 108: 985-1009, 2001. (Pubitemid 32802096)
27. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, and Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122, 2006. (Pubitemid 44894520)
28. Lang AE. Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat Med 16: 1223-1226, 2010.
29. Langston JW, Ballard P, Tetrud JW, and Irwin I. Chronic Parkinsonism in humans due to a product of meperidineanalog synthesis. Science 219: 979-980, 1983. (Pubitemid 13189531)
30. Larsson NG. Somatic mitochondrial DNA mutations in mammalian aging. Annu Rev Biochem 79: 683-706, 2010.
31. LeWitt PA. Clinical trials of neuroprotection for Parkinson's disease. Neurology 63: S23-S31, 2004.
32. Mandel S, Weinreb O, Amit T, and Youdim MB. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev 48: 379-387, 2005. (Pubitemid 40590050)
33. Maruyama W and Naoi M. Neuroprotection by (-)-deprenyl and related compounds. Mech Ageing Dev 111: 189-200, 1999.
34. Maruyama W, Weinstock M, Youdim MB, Nagai M, and Naoi M. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett 341: 233-236, 2003. (Pubitemid 36403771)
35. Matsubara K, Senda T, Uezono T, Awaya T, Ogawa S, Chiba K, Shimizu K, Hayase N, and Kimura K. L-Deprenyl prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP( + ) and beta-carbolinium: a microdialysis study in rats. Neurosci Lett 302: 65-68, 2001. (Pubitemid 32274210)
36. Morgan-Hughes JA, Schapira AH, Cooper JM, and Clark JB. Molecular defects of NADH-ubiquinone oxidoreductase (complex I) in mitochondrial diseases. J Bioenerg Biomembr 20: 365-382, 1988.
37. Murphy MP and Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 47: 629-656, 2007.
38. Naoi M and Maruyama W. Future of neuroprotection in Parkinson's disease. Parkinsonism Relat Disord 8: 139-145, 2001. (Pubitemid 32728027)
39. Narendra D, Tanaka A, Suen DF, and Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183: 795-803, 2008.
40. Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, Cookson MR, and Youle RJ. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 8: e1000298, 2010.
41. Nicklas WJ, Vyas I, and Heikkila RE. Inhibition of NADHlinked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36: 2503-2508, 1985. (Pubitemid 15072756)
42. Olanow CW, Schapira AH, LeWitt PA, Kieburtz K, Sauer D, Olivieri G, Pohlmann H, and Hubble J. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 5: 1013-1020, 2006. (Pubitemid 44709968)
43. Olanow CW, Kieburtz K, and Schapira AH. Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol 64 Suppl 2: S101-S110, 2008.
44. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, and Tolosa E. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361: 1268-1278, 2009.
45. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66: 664-671, 2006.
46. Plun-Favreau H, Klupsch K, Moisoi N, Gandhi S, Kjaer S, Frith D, Harvey K, Deas E, Harvey RJ, McDonald N, Wood NW, Martins LM, and Downward J. The mitochondrial protease HtrA2 is regulated by Parkinson's diseaseassociated kinase PINK1. Nat Cell Biol 9: 1243-1252, 2007. (Pubitemid 350042356)
47. Poole AC, Thomas RE, Andrews LA, McBride HM, Whitworth AJ, and Pallanck LJ. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci USA 105: 1638-1643, 2008. (Pubitemid 351346567)
48. Pridgeon JW, Olzmann JA, Chin LS, and Li L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 5: e172, 2007.
49. Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, and Olanow CW. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 10: 415-423, 2011.
50. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, and Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434: 113-118, 2005. (Pubitemid 40349395)
51. Schapira AH. Mitochondrial diseases. Lancet [In press]: 2012.
52. Schapira AH. Science, medicine, and the future: Parkinson's disease. BMJ 318: 311-314, 1999. (Pubitemid 29195142)
53. Schapira AH. Etiology of Parkinson's disease. Neurology 66: S10-S23, 2006.
54. Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le NN, Obeso JA, Schwarzschild MA, Spampinato U, and Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 5: 845-854, 2006. (Pubitemid 44480538)
55. Schapira AH. The use of rasagiline in Parkinson's disease. J Neural Transm Suppl 157-161, 2006. (Pubitemid 351412117)
56. Schapira AH and Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 59: 559-562, 2006. (Pubitemid 43358078)
57. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 7: 97-109, 2008. (Pubitemid 350251942)
58. Schapira AH. Rasagiline in neurodegeneration. Exp Neurol 212: 255-257, 2008.
59. Schapira AH. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology 72: S44-S50, 2009.
60. Schapira AH, Emre M, Jenner P, and Poewe W. Levodopa in the treatment of Parkinson's disease. Eur J Neurol 16: 982-989, 2009.
61. Schapira AH. Neurobiology and treatment of Parkinson's disease. Trends Pharmacol Sci 30: 41-47, 2009.
62. Schapira AH, Agid Y, Barone P, Jenner P, Lemke MR, Poewe W, Rascol O, Reichmann H, and Tolosa E. Perspectives on recent advances in the understanding and treatment of Parkinson's disease. Eur J Neurol 16: 1090-1099, 2009.
63. Schapira AH. Movement disorders: advances in cause and treatment. Lancet Neurol 9: 6-7, 2010.
64. Schapira AH and Tolosa E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol 6: 309-317, 2010.
65. Schapira AH and Schrag A. Parkinson disease: Parkinson disease clinical subtypes and their implications. Nat Rev Neurol 7: 247-248, 2011.
66. Schapira AH. Challenges to the development of diseasemodifying therapies in Parkinson's disease. Eur J Neurol 18 Suppl 1: 16-21, 2011.
67. Sharma SK, Carlson EC, and Ebadi M. Neuroprotective actions of Selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+ )-induced apoptosis in SK-N-SH neurons. J Neurocytol 32: 329-343, 2003. (Pubitemid 38197813)
68. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troconso JC, Dawson VL, and Dawson TM. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 144: 689-702, 2011.
69. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, and Lew M. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59: 1541-1550, 2002.
70. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, and Spiegelman BM. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127: 397-408, 2006. (Pubitemid 44572377)
71. Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, Muller T, Kupsch A, Henningsen H, Oertel WH, Fuchs G, Kuhn W, Niklowitz P, Koch R, Herting B, and Reichmann H. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol 64: 938-944, 2007. (Pubitemid 47047992)
72. Tain LS, Mortiboys H, Tao RN, Ziviani E, Bandmann O, and Whitworth AJ. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci 12: 1129-1135, 2009.
73. Tatton W, Chalmers-Redman R, and Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 110: 509-515, 2003. (Pubitemid 36543282)
74. Tatton WG and Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 30: 666-672, 1991.
75. Tatton WG, Ju WY, Holland DP, Tai C, and Kwan M. Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63: 1572-1575, 1994. (Pubitemid 24299550)
76. Tatton WG and Chalmers-Redman RM. Modulation of gene expression rather than monoamine oxidase inhibition: Deprenyl-related compounds in controlling neurodegeneration. Neurology 47: S171-S183, 1996. (Pubitemid 26422583)
77. Tatton WG, Chalmers-Redman RM, Ju WJ, Mammen M, Carlile GW, Pong AW, and Tatton NA. Propargylamines induce antiapoptotic new protein synthesis in serum-and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther 301: 753-764, 2002. (Pubitemid 34429993)
78. The Huntington Study Group. A randomized, placebocontrolled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57: 397-404, 2001.
79. The NINDS BET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68: 20-28, 2007.
80. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 321: 1364-1371, 1989.
81. Verdin E, Hirschey MD, Finley LW, and Haigis MC. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci 35: 669-675, 2010.
82. Vives-Bauza C, Zhou C, Huang Y, Cui M, de Vries RL, Kim J, May J, Tocilescu MA, Liu W, Ko HS, Magrane J, Moore DJ, Dawson VL, Grailhe R, Dawson TM, Li C, Tieu K, and Przedborski S. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci USA 107: 378-383, 2010.
83. Wang C and Youle RJ. The role of mitochondria in apoptosis. Annu Rev Genet 43: 95-118, 2009.
84. Youdim MB, Wadia A, Tatton W, and Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann N Y Acad Sci 939: 450-458, 2001. (Pubitemid 32620098)
85. Youdim MB and Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5- YL)-ethyl methyl carbamate]. Cell Mol Neurobiol 21: 555-573, 2001. (Pubitemid 34538855)
86. Youdim MB, Gross A, and Finberg JP. Rasagiline [N-propargyl-1R( + )-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132: 500-506, 2001. (Pubitemid 32142364)